No Data
No Data
(IMAB) - Analyzing I-MAB's Short Interest
I-MAB's (NYSE:IMAB) short percent of float has risen 113.98% since its last report. The company recently reported that it has 1.30 million shares sold short, which is 3.98% of all regular shares that
Patent Law Changes Pose Threat to I-Mab Adr's Drug Candidate Protection
I-MAB Filed 2023 Annual Report on Form 20-F
ROCKVILLE, Md., April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of hig
Verastem Names John Hayslip as Chief Medical Officer
Verastem (VSTM) said late Thursday it appointed John Hayslip as chief medical officer, succeeding Louis Denis, who recently left the company. Hayslip most recently served as the chief medical officer
I-Mab Announces CMO Transition, Interim Successor Named
Needham: Reiterates the IMAB.US rating and adjusted from buy to buy, with a target price of $6.00.
Needham: Reiterates the IMAB.US rating and adjusted from buy to buy, with a target price of $6.00.